ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: However, tyrosine kinase inhibitors have cytotoxic effects in only a few hematologic malignancies with BCR-ABL fusion genes including CML, myelodysplastic syndrome [16], and BCR-ABL-positive MM [17].